THE USE OF CANNABIDIOL AS A TREATMENT FOR ALZHEIMER'S DISEASEABSTRACT

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative condition with no definitive treatment. It is characterized by cognitive and memory deterioration, gradual impairment, and behavioral changes. Cannabidiol has various properties, including antioxidant, anti-inflammatory, and neuroprotective activities. Additionally, preliminary evidence from studies suggests that its use may improve symptoms such as agitation and sleep disturbances. However, there is significant room for understanding the exact mechanisms by which Cannabidiol exerts its neuroprotective effects, as well as its long-term efficacy and safety in patients. This study aims to conduct a literature review on Cannabidiol (CBD) as a potential therapeutic for Alzheimer's disease. A bibliographic survey was conducted in databases using descriptors in Portuguese, English, and Spanish to obtain relevant studies on the topic, utilizing the PUBMED, BVS, and SCIELO databases, covering the period from 2006 to 2024. The results demonstrated that CBD reverses and prevents the development of cognitive deficits, providing and validating approaches that CBD, and possibly CBD-THC (delta-9-tetrahydrocannabinol) combinations, are valid candidates for new therapies against AD. Future studies should explore the long-term potential of CBD by evaluating the underlying mechanisms of the mentioned therapeutic effects and ensuring regulatory compliance with current legislation. Although there is promising preliminary evidence, additional clinical studies are necessary to develop more effective approaches for the treatment of this neurodegenerative disease.